62 results
8-K
EX-99.1
ALXO
Alx Oncology Holdings Inc
9 May 24
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
are sufficient to fund planned operations well into Q1 2026.
Research and Development (“R&D”) Expenses: R&D expenses consist primarily of pre-clinical … and per share amounts)
Three Months Ended
March 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
8-K
EX-99.1
ALXO
Alx Oncology Holdings Inc
7 Mar 24
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:05pm
an additional $40 million of its term loan are sufficient to fund planned operations into early 2026.
Research and Development (“R&D”) Expenses: R&D … of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future
8-K
EX-99.1
ot5sn5n1ev4igrw
13 Nov 23
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
424B5
t59x1l0xu 7ldsm03lgb
6 Oct 23
Prospectus supplement for primary offering
6:05am
424B5
t6ov5rq07fi76d
4 Oct 23
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
0z67e2k
4 Oct 23
Other Events
8:00am
424B3
gwh4vt204k8kicpr8
8 Sep 23
Prospectus supplement
4:25pm
8-K
EX-99.1
wr6uz1kszic
6 Sep 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
8jj1snwbq xn
10 Aug 23
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
4:05pm
8-K
EX-99.1
anj3g 3ufg
11 May 23
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
4:03pm
8-K
EX-99.1
8jq pmjra870x6
29 Nov 22
ALX Oncology Appoints Scott Garland to its Board of Directors
9:11am